The Bone-Vascular Axis in Chronic Kidney Disease: From Pathophysiology to Treatment.

Adynamic bone CKD-MBD Hyperparathyroidism Osteoporosis Vascular calcification Wnt/β-catenin

Journal

Current osteoporosis reports
ISSN: 1544-2241
Titre abrégé: Curr Osteoporos Rep
Pays: United States
ID NLM: 101176492

Informations de publication

Date de publication:
10 Jan 2024
Historique:
accepted: 26 12 2023
medline: 10 1 2024
pubmed: 10 1 2024
entrez: 10 1 2024
Statut: aheadofprint

Résumé

This review aims to describe the pathogenic factors involved in bone-vessel anomalies in CKD which are the object of numerous experimental and clinical research. Knowledge on the pathophysiological mechanisms involved in the regulation of vascular calcification and mineral-bone disorders is evolving. Specific bone turnover anomalies influence the vascular health while recent studies demonstrate that factors released by the calcified vessels also contribute to bone deterioration in CKD. Current therapies used to control mineral dysregulations will impact both the vessels and bone metabolism. Available anti-osteoporotic treatments used in non-CKD population may negatively or positively affect vascular health in the context of CKD. It is essential to study the bone effects of the new therapeutic options that are currently under investigation to reduce vascular calcification. Our paper highlights the complexity of the bone-vascular axis and discusses how current therapies may affect both organs in CKD.

Identifiants

pubmed: 38195897
doi: 10.1007/s11914-023-00858-8
pii: 10.1007/s11914-023-00858-8
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Clément Vachey (C)

CHU de Québec Research Center, L'Hôtel-Dieu de Québec Hospital, Endocrinology and Nephrology Axis, Faculty and Department of Medicine, Université Laval, 10 McMahon, Quebec City, Quebec, G1R 2J6, Canada.

Alexandre Candellier (A)

CHU de Québec Research Center, L'Hôtel-Dieu de Québec Hospital, Endocrinology and Nephrology Axis, Faculty and Department of Medicine, Université Laval, 10 McMahon, Quebec City, Quebec, G1R 2J6, Canada.

Soline Toutain (S)

CHU de Québec Research Center, L'Hôtel-Dieu de Québec Hospital, Endocrinology and Nephrology Axis, Faculty and Department of Medicine, Université Laval, 10 McMahon, Quebec City, Quebec, G1R 2J6, Canada.

Fabrice Mac-Way (F)

CHU de Québec Research Center, L'Hôtel-Dieu de Québec Hospital, Endocrinology and Nephrology Axis, Faculty and Department of Medicine, Université Laval, 10 McMahon, Quebec City, Quebec, G1R 2J6, Canada. fabrice.mac-way.med@ssss.gouv.qc.ca.

Classifications MeSH